Advanced Proteome is simplifying and standardizing the production of antibody drug conjugates (ADC) to treat cancer, using proprietary site-selective chemistries as protein modification technologies.
Our site-selective labeling technology platform is called Universal Antibody Connectors™ (UAC). Our approach allows us to generate antibody drug conjugate candidates, which are more uniform and homogenous than the current state of the art. This is critical to maximize manufacturability and efficacy of an ADC. The UAC technology platform allows us to simplify and standardize the generation of ADC candidates for screening and further development.
Through academic and industrial partnerships, we have established a discovery stage ADC product pipeline, including proprietary antibodies and toxins. We will either partner to establish discovery proof of concept or take proprietary ADC product candidates into the clinic, as appropriate.
A promising opportunity
Despite the huge promise of ADCs, particularly in anti-tumor therapy, their effectiveness, ease of manufacturing and clinical potential has been limited by several factors, including the production of complex mixtures rather than ideally a single, pure, active constituent. Many hundreds of antibody candidates have been developed by a large number of companies and institutions. There also exists a number of functional proteins, which could serve as “payloads” on a targeting antibody.
Significant gaps exist in the linker chemistry technology that allows the formation of ADCs. Most notably, non-specific methods for producing ADCs often lead to complicated mixtures, and have been cumbersome and challenging to scale for manufacturing purposes.
To perfect ADC products and minimize labor intensive and costly manufacturing processes, as well as increase the odds for regulatory approvals, a linker technology that can attach to a specific site on an antibody must be developed. Advanced Proteome is currently advancing technology with broad commercial potential to overcome some of the limitations of traditional ADCs.
We use proprietary site-selective chemistries as protein modification technologies. By applying the UAC technology, we are able to label antibodies with a modular, customizable linker technology, without leaving the extraneous targeting elements on the resulting entity.
Advanced Proteome has demonstrated selectivity of labeling using quantitative detection methods, which we developed for this purpose. We can detect a profile consistent with labeling a site selectively at targeted regions of the antibody (e.g., the clinically efficacious and commercially successful antibody, Trastuzumab).
Advanced Proteome is advancing our labeling technology through two parallel paths:
- Licensing our linker technology to companies for the development of their own therapeutics
- Creating ADC product candidates based on novel antibodies in combination with our linker technology